Healthcare Services

Global Irritable Bowel Syndrome (IBS) Treatment Market Anticipated To Grow To $10.64 Billion By 2030 At 7.5% CAGR

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Irritable Bowel Syndrome (IBS) Treatment Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The irritable bowel syndrome (ibs) treatment market has shown significant expansion in recent years. It is anticipated to increase from $7.41 billion in 2025 to $7.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. This historical growth can be linked to the rising incidence of gastrointestinal disorders, improved ibs diagnosis rates, increasing knowledge about digestive health, the accessibility of prescription ibs medications, and the expanding presence of hospital and retail pharmacy networks.

The irritable bowel syndrome (ibs) treatment market size is anticipated to undergo significant expansion in the coming years. Its valuation is projected to reach $10.65 billion by 2030, displaying a compound annual growth rate (CAGR) of 7.5%. This growth throughout the forecast period is driven by advancements in precision medicine, the increasing adoption of digital health platforms, the expansion of online pharmacy channels, a heightened focus on microbiome research, and rising healthcare expenditure for chronic conditions. Notable trends for the forecast period encompass precision medicine and microbiome-based therapies, the integration of digital therapeutics and mobile health, AI-driven ibs diagnosis and treatment optimization, remote patient monitoring combined with smart gut health devices, and sustainable, patient-centric drug development.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp

Which Major Factors Are Contributing To The Development Of The Irritable Bowel Syndrome (IBS) Treatment Market?

The increasing prevalence of Irritable Bowel Syndrome (IBS) is projected to propel the expansion of the IBS treatment market. IBS is a chronic gastrointestinal condition impacting the large intestine, causing symptoms such as constipation, diarrhea, abdominal pain, and bloating, thereby significantly diminishing quality of life. The rise in IBS cases is attributable to lifestyle factors, including inadequate diet, stress, and environmental exposures, which contribute to more individuals developing the disorder. The IBS treatment market caters to patient needs by offering both pharmacological interventions, such as antispasmodics and gut-targeted medications, and non-pharmacological approaches, including cognitive behavioral therapy, hypnotherapy, and dietary management. As an illustration, in December 2023, the IBD Registry, a UK-based non-profit organization, announced it had reached over 5,300 individuals with Inflammatory Bowel Disease (IBD) by 2023, representing an increase of more than 3,000 members compared to 2022. This demonstrates how the rising incidence of IBS is driving the growth of the IBS treatment market.

How Is The Irritable Bowel Syndrome (IBS) Treatment Market Distributed Across Key Segments?

The irritable bowel syndrome (ibs) treatment market covered in this report is segmented –

1) By Drug Type: Eluxadoline, Alosetron, Other Drugs

2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

4) By End-Users: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment, Moderate IBS-D Treatment

2) By Alosetron: Severe IBS-D Treatment for Women, Refractory IBS-D Treatment

3) By Other Drugs: Prucalopride, Tenapanor, Plecanatide

Which Trends Are Shaping The Irritable Bowel Syndrome (IBS) Treatment Market Landscape?

Leading companies within the irritable bowel syndrome (IBS) treatment market are increasingly integrating digital therapeutics, such as mobile applications rooted in gut-directed hypnotherapy, to boost patient involvement, broaden access to treatment, and improve symptom control. These gut-directed hypnotherapy–based mobile applications represent prescription digital platforms that deliver structured hypnotherapy sessions via a smartphone interface, aiming to regulate gut–brain interaction and offer functionalities like guided behavioural therapy, real-time symptom monitoring, and automated tracking of patient progress. As an illustration, in May 2023, Launchit DTx, a digital health commercialization company based in Canada, unveiled Regulora, a digital therapeutic centered on gut-directed hypnotherapy, specifically crafted to assist adults in managing abdominal pain linked with irritable bowel syndrome (IBS). Regulora incorporates evidence-based hypnotherapy modules, clinician-enabled prescribing processes, and a mobile application for ongoing patient response tracking. By providing a non-pharmacologic, digitally administered therapeutic choice, Regulora enhances treatment accessibility, facilitates self-management, and contributes to overall symptom alleviation for IBS patients.

Who Are The Major Companies Operating In The Irritable Bowel Syndrome (IBS) Treatment Market?

Major companies operating in the irritable bowel syndrome (ibs) treatment market are Ironwood Pharmaceuticals Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson Services Inc., AstraZeneca plc, Novartis AG, Abbott Laboratories, Eli Lilly and Company, Astellas Pharma Inc., Bausch Health Companies Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc., Salix Pharmaceuticals Ltd., Allergan plc, Synergy Pharmaceuticals Inc.

Access The Complete Irritable Bowel Syndrome (IBS) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

Which Region Stands As The Largest Contributor To The Irritable Bowel Syndrome (IBS) Treatment Market?

North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Irritable Bowel Syndrome (IBS) Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=11978&type=smp

Browse Through More Reports Similar to the Global Irritable Bowel Syndrome (IBS) Treatment Market 2026, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Bowel Management Systems Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

Constipation Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/constipation-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795